Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EADO Congress 2015

28 - 31 Oct 2015
Palais du Pharo, Marseille, France
What is the relationship between PD-L1 expression and antitumour activity?
Dr Paolo Ascierto - National Tumor Institute, Naples, Italy
What is the relationship between PD-L1 expression and antitumour activity? ( Dr Paolo Ascierto - National Tumor Institute, Naples, Italy )
19 Nov 2015
Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients
Prof Philippe Saiag - University of Versailles, Versailles, France
Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients ( Prof Philippe Saiag - University of Versailles, Versailles, France )
5 Nov 2015
What are the prognostic values of 25-hydroxyvitamin D3 levels at diagnosis and f...
Prof Philippe Saiag - University of Versailles, Versailles, France
What are the prognostic values of 25-hydroxyvitamin D3 levels at diagnosis and follow-up? ( Prof Philippe Saiag - University of Versailles, Versailles, France )
5 Nov 2015
Anti-PD1 or tyrosine kinase inhibitors?
Dr Mark Middleton - University of Oxford, Oxford, UK
Anti-PD1 or tyrosine kinase inhibitors? ( Dr Mark Middleton - University of Oxford, Oxford, UK )
5 Nov 2015
New drugs and new trials in melanoma
Prof Jean-Jacques Grob - Marseille University, Marseille, France
New drugs and new trials in melanoma ( Prof Jean-Jacques Grob - Marseille University, Marseille, France )
5 Nov 2015
Highlights of EADO 2015
Prof Jean-Jacques Grob - Marseille University, Marseille, France
Highlights of EADO 2015 ( Prof Jean-Jacques Grob - Marseille University, Marseille, France )
5 Nov 2015
Disruptive technologies in cancer
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Disruptive technologies in cancer ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
5 Nov 2015
Latest from the CoBRIM study
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Latest from the CoBRIM study ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
5 Nov 2015
Anti-PD-1 or anti-CTLA-4 in first line therapy?
Prof Claus Garbe - University of Tübingen, Tübingen, Germany
Anti-PD-1 or anti-CTLA-4 in first line therapy? ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )
5 Nov 2015
Long response and long responders in melanoma immunology
Prof Georgina Long - University of Sydney, Sydney, Australia
Long response and long responders in melanoma immunology ( Prof Georgina Long - University of Sydney, Sydney, Australia )
5 Nov 2015
What is the real role of UV in melanoma?
Dr Amaya Viros - The University of Manchester, Manchester, UK
What is the real role of UV in melanoma? ( Dr Amaya Viros - The University of Manchester, Manchester, UK )
5 Nov 2015
The Co-BRIM study: Quality-of-life assessment in patients with metastatic melano...
Prof Brigitte Dreno - Nantes University Hospital, Nantes, France
The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma ( Prof Brigitte Dreno - Nantes University Hospital, Nantes, France )
5 Nov 2015
Benefit and risk analysis from the phase III OPTiM trial
Dr Kevin Harrington - Institute of Cancer Research, London, UK
Benefit and risk analysis from the phase III OPTiM trial ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )
5 Nov 2015
Progress in targeted therapy of melanoma
Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA
Progress in targeted therapy of melanoma ( Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA )
5 Nov 2015
Melanoma prevention: Do we need sunlight for vitamin D?
Prof Julia A Newton-Bishop - University of Leeds, Leeds, UK
Melanoma prevention: Do we need sunlight for vitamin D? ( Prof Julia A Newton-Bishop - University of Leeds, Leeds, UK )
5 Nov 2015
Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study
Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany
Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study ( Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany )
5 Nov 2015
Why is screening for melanoma important?
Prof Iris Zalaudek - Medical University of Graz, Graz, Austria
Why is screening for melanoma important? ( Prof Iris Zalaudek - Medical University of Graz, Graz, Austria )
5 Nov 2015
Management of acute metastatic melanoma
Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK
Management of acute metastatic melanoma ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )
5 Nov 2015
How should we handle talimogene laherparepvec (T-VEC)?
Prof Axel Hauschild - University of Kiel, Kiel, Germany
How should we handle talimogene laherparepvec (T-VEC)? ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )
5 Nov 2015
New challenges in drug combination and strategies
Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK
New challenges in drug combination and strategies ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )
5 Nov 2015
Targeting N-RAS mutated tumours
Prof Axel Hauschild - University of Kiel, Kiel, Germany
Targeting N-RAS mutated tumours ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )
30 Oct 2015
HVEM expression in melanoma metastasis: prognosis correlation
Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France
HVEM expression in melanoma metastasis: prognosis correlation ( Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France )
30 Oct 2015
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
Prof Axel Hauschild - University of Kiel, Kiel, Germany
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )
30 Oct 2015